AMAG Pharmaceuticals Announces Closing of $201 Million Public Offering of Common Stock Including Full Exercise of Underwriter...
March 03 2015 - 5:00PM
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today the
closing of its previously announced public offering of common
stock, including the exercise in full by the underwriters of their
option to purchase an additional 596,590 shares of common stock at
the public offering price of $44.00 per share. The exercise of the
underwriters' option brought the total number of shares of common
stock sold by AMAG to 4,573,862 and increased the total gross
proceeds raised in the offering to approximately $201.2 million,
before deducting underwriting discounts, commissions and estimated
expenses.
J.P. Morgan and Deutsche Bank Securities acted as joint
book-running managers for the offering. Cowen and Company and Baird
acted as co-managers for the offering.
The public offering was made pursuant to an automatic shelf
registration statement on Form S-3ASR that was previously filed
with the Securities and Exchange Commission (SEC). A final
prospectus supplement relating to the offering has been filed with
the SEC and is available on the website of the SEC at
www.sec.gov. Copies of the final prospectus supplement and
accompanying base prospectus relating to the offering may also be
obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by
telephone: +1 (866) 803-9204 or from Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY
10005-2836 or by telephone: +1 (800) 503-4611 or by email:
prospectus.CPDG@db.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. Any offers, solicitations of offers to buy, or sales
of the common stock will only be made pursuant to the registration
statement filed with the SEC, including a prospectus and a related
preliminary prospectus supplement.
About AMAG
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company
with a focus on maternal health, anemia and cancer supportive
care. The primary goal of AMAG is to bring to market therapies
that provide clear benefits and improve patients' lives. In
addition to continuing to pursue opportunities to make new
advancements in patients' health and to enhance treatment
accessibility, AMAG intends to continue to expand and diversify its
portfolio through the in-license or purchase of additional
pharmaceutical products or companies.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws. Any statements contained herein
which do not describe historical facts are forward-looking
statements which involve risks and uncertainties that could cause
actual results to differ materially from those discussed in such
forward-looking statements.
Such risks and uncertainties include, among others, the risks
identified in AMAG's filings with the U.S. Securities and Exchange
Commission (SEC), including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2014 and subsequent filings with the
SEC. Any of these risks and uncertainties could materially and
adversely affect AMAG's results of operations, its profitability
and its cash flows, which would, in turn, have a significant and
adverse impact on AMAG's stock price. AMAG cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made.
CONTACT: AMAG Pharmaceuticals, Inc. Contact:
Katie Payne, 617-498-3303
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2023 to Apr 2024